Results 111 to 120 of about 15,210 (229)

Epigenetics and chromatin remodeling play a role in lung disease [PDF]

, 2011
Epigenetics is defined as heritable changes that affect gene expression without altering the DNA sequence. Epigenetic regulation of gene expression is facilitated through different mechanisms such as DNA methylation, histone modifications and RNA ...
Adcock, IM, Barnes, PJ, Masjedi, MR, Mortaz, E   +3 more
core   +1 more source

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. [PDF]

, 2011
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose-escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory or ...
Forman, SJ, Frankel, P, Karanes, C, Kirschbaum, MH, Newman, EM, O'Donnell, MR, Popplewell, L, Pulone, B, Rincon, A, Stein, AS, Synold, T, Tuscano, J, Wright, J, Zain, JM   +13 more
core  

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study

Blood and Lymphatic Cancer: Targets and Therapy
Na Zhao,1,2,* Lijun Zhu,1,* Xing Hu,1,* Juan Tong,1 Hongfeng Ge,3 Li Ye,4 Xijun Zhu,5 Can Gai,6 Yuhu Feng,7 Lei Zhang,1 Li Wang,1 Guangyu Sun,1 Lei Xue,1 Xiaoyu Zhu,1 Changcheng Zheng1,8 1Department of Hematology, the First ...
Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, Zhu X, Gai C, Feng Y, Zhang L, Wang L, Sun G, Xue L, Zhu X, Zheng C   +14 more
doaj  

HYPOMETHYLATING AGENTS IN TREATMENT OF MYELODYSPLASTIC SYNDROME

EUREKA: Health Sciences, 2018
Thelkey to the successful treatment of myelodysplastic syndrome is the careful characterization and diagnosis of the disease, which includes clinical, cytogenetic, biological and molecular investigation of individual patients. Today therapeutic approaches to the treatment of such patients are differentiated and depend, first of all, on the subtype of ...
openaire   +2 more sources

Managing myelodysplastic syndromes in very old patients: a teaching case report

Clinical Interventions in Aging, 2013
Pasquale Niscola, Massimiliano Palombi, Malgorzata Monika Trawinska, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Alessio Perrotti, Paolo de Fabritiis Hematology Unit, Sant'Eugenio Hospital, Rome, Italy Abstract: The introduction of ...
Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P   +7 more
doaj  

Serendipity: Decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia [PDF]

, 2019
Abboud, Camille N, Abboud, Ramzi, Cashen, Amanda F, DiPersio, John F, Duncavage, Eric J, Han, Se Young, Shirai, Cara Lunn, Welch, John S   +7 more
core   +3 more sources

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients

Frontiers in Oncology
This study aimed to investigate the efficacy, safety and prognostic value of measurable residual disease (MRD) in unfit AML patients treated with long-course venetoclax combined with hypomethylating agents, so as to provide evidence for optimizing ...
Chen Cao, Minran Zhou, Xinwen Jiang, Qingli Ji, Xiaoqing Li, Sai Ma, Chunyan Chen, Chunyan Chen, Chunyan Chen   +8 more
doaj   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

Journal of Scientific Innovation in Medicine, 2020
Abigail Belasen, Shyamala Navada
doaj   +1 more source

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study

Hematology
Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML ...
Fei Xin, Yan-Hui Yu, Xu-Liang Shen, Guo-Xiang Zhang   +3 more
doaj   +1 more source